Jan. 10, 2025

The U.S. Food and Drug Administration (FDA) seeks public comments on draft guidance it published Jan. 7. Of particular interest to the American College of Radiology® (ACR®) is “Artificial Intelligence (AI)-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations.”

The industry guidance outlines a total product lifecycle (TPLC) approach to risk management of AI device software functions, as well as related documentation to support FDA review. It also provides recommendations relevant to transparency and bias mitigation throughout the TPLC, including within the product’s user interface and labelling.

The ACR Informatics Commission and Data Science Institute® (DSI) leadership are reviewing the guidance. The College’s initiatives related to AI are on the DSI website.

Public comments are due to the FDA by April 7.

If you have questions or would like more information about ACR AI/digital health policy, contact Michael Peters, ACR Senior Director, Government Affairs.


Related ACR News

  • ACR 2025 Economics Forum

    The Economics Forum at ACR 2025 highlighted recent successes including coverage of CT colonoscopy for Medicare patients and new CPT codes for MRI safety.

    Read more
  • Radiology Advocacy Begins Now

    Medical student, Annie Pham, BS, M3 of Edward Via College of Osteopathic Medicine, Louisiana Campus, discusses her experiences during the 2025 ACR Capitol Hill Day.

    Read more
  • Connections Through Advocacy: Familiar Faces Along the Interview Trail

    Read more